公开(公告)号：EP1255541A2

公开(公告)日：2002-11-13

申请号：EP01911580.7

申请日：2001-02-02

申请人： Axxima Pharmaceuticals Aktiengesellschaft

发明人： BEVEC, Dorian ,  HAUBER, Joachim ,  OBERT, Sabine ,  KERI, Gyorgy ,  ORFI, Laszlo ,  SZEKELY, Istvan ,  CHOIDAS, Axel ,  BACHER, Gerald

IPC分类号： A61K31/155 ,  A61P31/18 ,  A61K31/22 ,  A61P31/04

CPC分类号： A61K45/06 ,  A61K31/155 ,  A61K31/17 ,  A61K31/4164 ,  C07C281/18 ,  Y02A50/402 ,  Y02A50/47 ,  Y02A50/471 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/479 ,  Y02A50/481

摘要： The present invention relates to aromatic guanylhydrazone compounds and their use as pharmaceutically active agents, especially for prophylaxis and treatment of virally caused diseases and infections, including opportunistic infections. The inventive guanylhydrazone compounds are also useful as inhibitors of deoxyhypusine synthase and as inhibitors for nuclear export in infectious diseases and may be used to regulate bacterially induced TNF-alpha production. Furthermore, the aromatic guanylhydrazones exhibit antibacterial activity against Gram positive and Gram negative bacteria and can be regarded as a novel class of antibiotics. In addition, methods for prophylaxis and treatment of virally or bacterially induced infections and diseases are disclosed together with pharmaceutical compositions useful within said methods containing at least one aromatic guanylhydrazone of the present invention as active ingredient.

公开(公告)号：EP1246630A1

公开(公告)日：2002-10-09

申请号：EP00976613.0

申请日：2000-10-20

申请人： Marantech Holding, LLC

发明人： ANTELMAN, Marvin, S.

IPC分类号： A61K33/00 ,  A61K33/24 ,  A61K33/26 ,  A61K33/34 ,  A61K33/38

CPC分类号： A61K8/0208 ,  A61K8/19 ,  A61K9/0014 ,  A61K9/06 ,  A61K33/24 ,  A61K33/245 ,  A61K33/26 ,  A61K33/32 ,  A61K33/34 ,  A61K33/38 ,  A61K47/02 ,  A61Q1/12 ,  A61Q19/00 ,  C01G3/02 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/393 ,  Y02A50/397 ,  Y02A50/40 ,  Y02A50/401 ,  Y02A50/402 ,  Y02A50/406 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/415 ,  Y02A50/463 ,  Y02A50/465 ,  Y02A50/469 ,  Y02A50/471 ,  Y02A50/478 ,  Y02A50/479 ,  Y02A50/481 ,  Y02A50/483 ,  Y02A50/491

摘要： The present invention is directed to pharmaceutical compositions that include a therapeutically effective amount of at least one electron active compound, or a pharmaceutically acceptable derivative thereof, that has at least two polyvalent cations, at least one of which has a first valence state and at least one of which has a second, different valence state. Preferred compounds include Bi(III,V) oxide, Co(II,III) oxide, Cu(I,III) oxide, Fe(II,III) oxide, Mn(II,III) oxide, and Pr(III,IV) oxide, and optionally Ag(I,III) oxide. These compounds may be in a crystalline state having metallic cations of two different valences, or electronic states, in the inorganic crystal. In addition, the invention relates to methods for prevention, management, or treatment of a condition using these compounds or pharmaceutical compositions including the same.

公开(公告)号：EP1231931A2

公开(公告)日：2002-08-21

申请号：EP00978467.9

申请日：2000-11-09

申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  Istituto Superiore Di Sanita

发明人： STROBER, Warren ,  FUSS, Ivan, J. ,  KELSALL, Brian, L. ,  BOIRIVANT, Monica

IPC分类号： A61K38/16 ,  A61P1/00 ,  A61P7/06 ,  A61P17/06 ,  A61P29/00

CPC分类号： A61K38/164 ,  Y02A50/471

摘要： The present invention provides a method of treating or preventing inflammation in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B. The present invention also provides a method of decreasing the activity of interferon gamma in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B. Further provided is a method of decreasing the activity of IL-12 in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B. Additionally, the present invention provides a method of treating or preventing a Th1 T-cell mediated autoimmune disorder in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B.

公开(公告)号：EP1209986A1

公开(公告)日：2002-06-05

申请号：EP00956712.4

申请日：2000-08-31

申请人： Remedy Research Limited

发明人： Hickock, Stephen SpauldingRemedy Research Limited

IPC分类号： A23L1/304 ,  A61K31/19 ,  A23L3/358 ,  C02F1/50 ,  C09K15/02 ,  A01N59/16 ,  A01N59/20 ,  C09D1/00

CPC分类号： C09D5/14 ,  A01N59/20 ,  A23L3/358 ,  A23L33/165 ,  A61K33/02 ,  A61K33/04 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K33/34 ,  A61K33/42 ,  C02F1/50 ,  Y02A50/471 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/481 ,  A61K33/00 ,  A61K31/19 ,  A61K2300/00 ,  A01N25/02 ,  A01N25/32 ,  A01N37/36 ,  A01N59/02 ,  A01N59/26

摘要： A metal-containing composition substantially comprising (i) at least one water soluble metal compound which forms metal ions when dissolved in water, (ii) at least one metal ion modifier as herein defined, (iii) at least one acid, and (iv) water said composition having a pH of less than 6 and an electrolytic potential in excess of 10 millivolts. Such compositions have uses in the prevention and/or treatment of pathogenic disease or disorder, as foodstuff supplements, in the treatment by disinfection of meat and other foodstuffs, in the coating, sealing and plating of metals, and treatment of water and sewage.

摘要翻译： 一种含金属的组合物，其基本上包含（i）至少一种当溶于水时形成金属离子的水溶性金属化合物，（ii）至少一种如本文所定义的金属离子改性剂，（iii）至少一种酸，和 ）水，所述组合物的pH小于6，电解电势超过10毫伏。 这些组合物在用于预防和/或治疗病原性疾病或病症中作为食品添加剂，在通过消毒肉类和其他食品的处理，金属的涂覆，密封和电镀以及处理水和污水中具有用途。

公开(公告)号：EP1203002A1

公开(公告)日：2002-05-08

申请号：EP00947701.9

申请日：2000-07-27

申请人： TRB Pharma Industria Quimica e Farmacéutica Ltda.

发明人： OLIVEIRA, Pedro Goncalves de ,  STORPIRTIS, Silvia

IPC分类号： C07H1/06 ,  C07H15/10 ,  A61K9/14 ,  A61K31/70 ,  A61P31/04

CPC分类号： C07H15/10 ,  A61K9/143 ,  A61K47/6923 ,  C07H1/06 ,  Y02A50/471

摘要： The invention provides a process to prepare a complex of adsorption charcoal-GM1 stable at different pH values. This process is based on the suspension method, the formulation example being presented. An analytical method to determine non derivatized GM1 in aqueous solutions using the high efficiency liquid chromatography technique is also object of the present invention.

公开(公告)号：EP1157110A1

公开(公告)日：2001-11-28

申请号：EP00908739.6

申请日：2000-02-22

申请人： Human Genome Sciences, Inc.

发明人： ROSEN, Craig, A. ,  NI, Jian ,  EBNER, Reinhard ,  YU, Guo-Liang

IPC分类号： C12N15/19 ,  C07K14/52 ,  C07K16/24 ,  A61K38/19

CPC分类号： C07K14/715 ,  A61K38/00 ,  C07K14/52 ,  C07K16/24 ,  C07K2317/34 ,  Y02A50/471

摘要： The present invention relates to a novel cytokine which has been designated Neutrokine-alpha ("Neutrokine-alpha"). In addition, an apparent splicing variant of Neutrokine-alpha has been identified and designated Neutrokine-alphaSV. In specific embodiments, the present invention provides nucleic acid molecules encoding Neutrokine-alpha and Neutrokine-alphaSV polypeptides. In additional embodiments, Neutrokine-alpha and Neutrokine-alphaSV polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same.

公开(公告)号：EP1070122A2

公开(公告)日：2001-01-24

申请号：EP99913854.8

申请日：1999-03-11

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： MCDONNELL, Timothy, J. ,  SWISHER, Stephen, G. ,  FANG, Bingliang ,  BRUCKHEIMER, Elizabeth, M. ,  SARKISS, Mona, G. ,  JI, Li ,  ROTH, Jack, A.

IPC分类号： C12N15/00 ,  A01N43/04

CPC分类号： C12N15/86 ,  A61K38/00 ,  A61K48/00 ,  C07K14/4747 ,  C12N2710/10343 ,  C12N2830/008 ,  Y02A50/471

摘要： The present invention generally relates to viral vectors and their use as expression vectors for transforming human cells, both in vitro and in vivo. More particularly, the present invention relates to adenoviral vectors containing propapoptotic genes and their use in cancer therapy.

公开(公告)号：EP0671943B1

公开(公告)日：1999-09-08

申请号：EP93914851.6

申请日：1993-06-30

申请人： Cortecs (UK) Limited

发明人： MYNOTT, Tracey Leahanne

IPC分类号： A61K38/45 ,  A61K38/48

CPC分类号： A61K38/4873 ,  Y02A50/471 ,  Y02A50/473

摘要： PCT No. PCT/GB93/01374 Sec. 371 Date Feb. 14, 1995 Sec. 102(e) Date Feb. 14, 1995 PCT Filed Jun. 30, 1993 PCT Pub. No. WO94/00147 PCT Pub. Date Jan. 6, 1994Enzymes, especially proteolytic enzymes such as bromelain, have been found to inhibit the action of heat-labile toxin (LT) of enterotoxigenic Escherichia coli. They are therefore useful in the prophylaxis, management and treatment of diarrhoea in humans.

公开(公告)号：EP0888062A1

公开(公告)日：1999-01-07

申请号：EP97916089.0

申请日：1997-03-19

申请人： Aquaculture Technology, Inc.

发明人： WANG, Jaw-Kai

IPC分类号： A61K36 ,  A01N37 ,  A01N63 ,  A61K31 ,  A61P31

CPC分类号： A01N63/02 ,  A01N37/06 ,  A01N63/00 ,  A61K35/68 ,  A61K36/185 ,  Y02A50/471 ,  Y02A50/475 ,  Y02A50/481 ,  Y10S435/946 ,  A61K2300/00

摘要： The present invention relates to the use of extracts obtained from the marine algae Chaetoceros as antibacterially active agents and to compositions containing such agents for use against pathogenic bacteria. This invention also relates to a method of depurating an aquiculture using as a feed source the marine algae Chaetoceros.

公开(公告)号：EP0769938B1

公开(公告)日：1998-10-28

申请号：EP95924940.0

申请日：1995-06-24

申请人： THERAPICON SRL

发明人： VERONESI, Paolo, Alberto

IPC分类号： A61K9/48

CPC分类号： A61K9/4816 ,  A61K9/4866 ,  A61K9/4891 ,  Y02A50/465 ,  Y02A50/471 ,  Y02A50/483

摘要： PCT No. PCT/EP95/02488 Sec. 371 Date Jan. 9, 1997 Sec. 102(e) Date Jan. 9, 1997 PCT Filed Jun. 24, 1995 PCT Pub. No. WO96/01612 PCT Pub. Date Jan. 25, 1996The present invention deals with a pharmaceutical product in unit dosage form and a unit dosage drug delivery system which comprises a multiple layer capsule or housing having two or more layers, the layers being of materials, wherein the outer layer possesses a hydrophilic character and the inner layer possesses a hydrophobic character, and a capsule filling wherein one or more drug substances are admixed, dissolved, suspended or agglomerated in a hydrophobic support.